Spark Therapeutics Inc. (NASDAQ:ONCE) shares were down 5.4% on Tuesday . The stock traded as low as $55.52 and last traded at $55.72, with a volume of 161,854 shares changing hands. The stock had previously closed at $58.87.

Several research analysts have weighed in on ONCE shares. Chardan Capital reissued a “neutral” rating on shares of Spark Therapeutics in a report on Thursday, April 14th. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 26th. Cowen and Company reissued a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a report on Wednesday, May 4th. Wedbush reissued an “underperform” rating and issued a $21.00 price target on shares of Spark Therapeutics in a report on Thursday, May 19th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a report on Monday, June 13th. Three analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $58.70.

The stock has a 50 day moving average of $51.61 and a 200-day moving average of $40.04. The stock’s market cap is $1.58 billion.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.11. The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.48 million. The company’s quarterly revenue was down 43.2% on a year-over-year basis. Equities research analysts forecast that Spark Therapeutics Inc. will post ($3.81) earnings per share for the current fiscal year.

In related news, Director Anand Mehra sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $60.00, for a total value of $30,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Stephen W. Webster sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the chief financial officer now directly owns 22,500 shares in the company, valued at approximately $1,133,775. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Spark Therapeutics stock. UBS Oconnor LLC purchased a new stake in Spark Therapeutics Inc. (NASDAQ:ONCE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $4,395,000. UBS Oconnor LLC owned about 0.39% of Spark Therapeutics as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.